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Background: Aberrant DNA methylation of regulatory genes has frequently been found in human breast cancers
and correlated to clinical outcome. In the present study we investigate stage specific changes in the DNA
methylation patterns in order to identify valuable markers to understand how these changes affect breast cancer
progression.
Methods: Quantitative DNA methylation analyses of 12 candidate genes ABCB1, BRCCA1, CDKN2A, ESR1, GSTP1, IGF2,
MGMT, HMLH1, PPP2R2B, PTEN, RASSF1A and FOXC1 was performed by pyrosequencing a series of 238 breast cancer
tissue samples from DCIS to invasive tumors stage I to IV.
Results: Significant differences in methylation levels between the DCIS and invasive stage II tumors were observed
for six genes RASSF1A, CDKN2A, MGMT, ABCB1, GSTP1 and FOXC1. RASSF1A, ABCB1 and GSTP1 showed significantly
higher methylation levels in late stage compared to the early stage breast carcinoma. Z-score analysis revealed
significantly lower methylation levels in DCIS and stage I tumors compared with stage II, III and IV tumors.
Methylation levels of PTEN, PPP2R2B, FOXC1, ABCB1 and BRCA1 were lower in tumors harboring TP53 mutations then
in tumors with wild type TP53. Z-score analysis showed that TP53 mutated tumors had significantly lower overall
methylation levels compared to tumors with wild type TP53. Methylation levels of RASSF1A, PPP2R2B, GSTP1 and
FOXC1 were higher in ER positive vs. ER negative tumors and methylation levels of PTEN and CDKN2A were higher
in HER2 positive vs. HER2 negative tumors. Z-score analysis also showed that HER2 positive tumors had significantly
higher z-scores of methylation compared to the HER2 negative tumors. Univariate survival analysis identifies
methylation status of PPP2R2B as significant predictor of overall survival and breast cancer specific survival.
Conclusions: In the present study we report that the level of aberrant DNA methylation is higher in late stage
compared with early stage of invasive breast cancers and DCIS for genes mentioned above.
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Breast cancer is the most common form of malignant
disease in women worldwide and also the principal cause
of death from cancer among women globally. In Norwegian
women breast cancer accounts for approximately 23% of
all cancers and ~800 women die as a result of the disease
every year. Breast cancer is a heterogeneous disease
with distinct histopathological, genetic and epigenetic
characteristics. Epigenetic regulation is critical for nor-
mal growth and development and provides a layer of
transcriptional control. Epigenetic alterations which
occur in transformed cells involve changes in DNA
methylation including global hypomethylation and focal
hypermethylation, histone modifications and nucleosomal
remodeling [1]. Epigenetic changes are considered to be
an early event in tumor development and one of the
hallmarks of cancer [2]. The degree of DNA methylation
in the promoter region of tumor suppressor genes, tran-
scription factors and drug response genes may play a
role in the initiation of cancer, tumor progression and
response to treatment. Identification of early epigenetic
changes in breast cancer might give valuable markers
for early detection and contribute to the understanding of
how these changes affect the progression of the disease
and prognosis for the patient. We previously described
treatment-specific DNA methylation patterns in 432 CpGs
in the promoter regions of 14 genes in samples from 75
patients with locally advanced breast cancer treated with
doxorubicin [3]. Further, we identified four novel genes
(ABCB1, FOXC1, PPP2R2B and PTEN) that were found
to be already aberrantly methylated in DCIS (Ductal
carcinoma in situ), a pre-invasive stage of breast cancer
[4] and that were also found to be methylated in the
locally advanced breast cancers [3]. These findings raised
the question if DNA methylation patterns evolve between
the different stages of breast cancers and pre-neoplastic
lesions or are similar and independent of tumor stage.
In the present study, using the same candidate gene
approach as previously described [3,4], we performed a
large-scale analysis of 12 candidate genes and determined
quantitatively the DNA methylation patterns of the 12
genes in 238 breast cancer patients of all stages from
early premalignant DCIS to advanced metastatic disease.
In addition to the analysis of stage dependent DNA
methylation patterns, associations between additional
clinico-pathological factors of breast cancer such as grade
and ER status and DNA methylation patterns of these 12
genes were assessed.
Methods
Patient material
A total of 238 samples were included in present study:
75 patients with locally advanced breast cancer that were
enrolled in a prospective study evaluating predictive factorsfor response to doxorubicin [3] and 35 patients treated with
5-FU and Mitomycin for locally advanced breast cancer [5],
patients in both cohorts were admitted to the Haukeland
University Hospital in Norway between 1991 and 2001;
57 samples from a series of 212 breast cancers samples
collected from Ullevål University Hospital (Norway)
between 1990 and 1994 [6]; 71 tumors from a population-
based cohort including 854 women diagnosed between
1986 and 2004 in Uppsala, Sweden with either: a) pure
ductal carcinoma in situ of the breast (DCIS), b) an invasive
breast cancer, 15 mm or less, without an in situ component
or c) a mixed lesion, i.e., a lesion with both an invasive-
and an in situ component [4]. Clinical and molecular
characteristics of the tumors are given in Table 1. DNA
from six normal breast tissues was included to identify the
DNA methylation baseline in normal tissues. Normal
breast tissue was obtained from women who underwent a
biopsy of the mammary gland because of mammographic
screening and for whom histology confirmed the presence
of only normal tissue. All patients had given informed
consent, and the project was approved by the local ethical
committee.
Methylation assays
DNA concentrations were determined using the Quant-iT™
dsDNA broad range assay kit (Invitrogen, Cergy Pontoise,
France) and normalized to a concentration of 50 ng/μl.
One μg of DNA was bisulphite converted using the
MethylEasy™ HT Kit for Centrifuge (Human Genetic
Signatures, North Ryde, Australia) according to the
manufacturer’s instructions. Quantitative DNA methyla-
tion analysis of the bisulphite treated DNA was performed
by pyrosequencing or - in case of several sequencing
primers - by serial pyrosequencing [7]. Oligonucleotides
for PCR amplification and pyrosequencing (Additional
file 1) were synthesized by Biotez (Buch, Germany) [3]. In
the present study, same candidate gene approach was used
as previously described [3,4] with the difference in number
of covered CpGs (205 in our case) because of absence
of variability. These genes were initially selected on the
following basis: previous reports of DNA methylation
in breast tumors or at least breast cancer cell lines (ABCB1
[8], BRCA1 [9], CDKN2A [9], ESR1 [10], GSTP1 [11],
IGF2 [12], MGMT [9], MLH1 [9], PPP2R2B [13], PTEN
[14], RASSF1A [15]) and genes displaying variation in
breast cancer gene expression profiles (FOXC1 [16]).
Statistical analysis
The average value of methylation for all CpGs in a target
region was calculated for each sample and each gene.
Although there was some stochastic variation between
different CpG positions, the overall methylation level was
quite constant and CpG positions were highly correlated
in the analyzed regions. A sample was considered 1)
Table 1 Clinical characteristics of the analyzed samples
Clinicopathological factor N(%)
Tumorsize
T0 26(11%)
T1 67(28.3%)
T2 35(14.8%)
T3 64(27%)
T4 45(18.9%)
Unknown 1
Stage
DCIS 26(11.5%)
I 65(28.9%)
II 20(8.9%)
III 92(40.9%)
IV 22(9.8%)
Unknown 13
Lymphnode status
N0 114(50.7%)
N1 76(34.9%)
N2 32(14.4%)
Unknown 16
Grade
G1 42(17.7%)
G2 128(54%)
G3 67(28.3%)
Unknown 1
HER2 status
Negative 60(57.1%)
Positive 45(42.9%)
Unknown 133
Progesteron receptor
Negative 69(29.2%)
Positive 167(70.8%)
Unknown 2
Estrogene receptor
Negative 53(22.7%)
Positive 180(77.3%)
Unknown 5
TP53 mutation
Wild type 174(73.4%)
Mutated 63(26.6%)
Unknown 1
Distant metastasis
No distant metastasis 214(90.3%)
Distant metastasis 23(9.7%)
Unknown 1
Table 1 Clinical characteristics of the analyzed samples
(Continued)
Molecular subtypes
Luminal A 52(30.8%)
Luminal B 34(20.1%)
ERRB2 29(17.2%)
Basal 37(21.9%)
Normal 17(10%)
Unknown 69
Unknown data was excluded from total when the percentage was calculated.
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http://www.biomedcentral.com/1471-2407/13/456hypermethylated if the percentage of DNA methylation
was higher than the sum of two times the standard devi-
ation and mean of the normal samples, 2) normal-like
methylation if the% DNA methylation was in range of two
times the standard deviation +/− mean of the normal
sample and 3) hypomethylated if% DNA methylation
was lower than two times standard deviation – mean
of normal sample. The aggregated quantitative DNA
methylation data is presented in Table 2. Differences in
the presence of methylation were determined by a two-
sided Fisher test (for variables with two categories) and
Chi- squared tests for variables with three or more
categories. Odds ratio and 95% confidence intervals were
calculated for two-categorical variables. Differences in
the distribution of methylation were assessed by the
non-parametric Mann–Whitney test (on parameters with
2 categories) or the Kruskal-Wallis test analysis on param-
eters with more than two categories. All obtained p-values
were corrected with the Bonferroni correction method
in which the p-values are multiplied by the number of
comparisons. The methylation index of samples (Z-score)
was calculated as: (methylation level of each sample – meanTable 2 Quantitative methylation data
Gene Mean of
samples
SD of
samples
Mean of
normal
SD of
normal
BRCA1 85.36 11.32 85.48 6.15
RASSF1A 30.92 17.34 3.37 0.99
PTEN 5.15 4.07 2.83 1.28
PPP2R2B 10.83 9.80 3.18 1.17
CDKN2A 4.68 4.64 3.58 1.08
MLH1 2.94 3.85 2.72 0.47
MGMT 4.21 3.53 4.48 1.11
ABCB1 16.18 17.25 2.63 1.23
IGF2 38.28 9.13 40.7 2.41
GSTP1 17.18 17.27 3.73 1.01
FOXC1 13.41 13.23 3.6 1.98
ESR1 2.92 2.50 4.43 2.94
Table 3 Methylation status of 12 genes in normal tissue, DCIS and invasive breast cancer patients
Normal DCIS Invasive
I II III IV
GENE Methylation status N % Sample
number
% Sample
number
% Sample
number
% Sample
number
% Sample
number
%
ABCB1 Hypomethylated 0 0 0 0 0 0 0
Normal like 6 100 15 57.7 33 52.4 6 30 31 36 6 30
Hypermethylated 0 11 42.3 30 47.6 14 70 57 64 14 70
BRCA1 Hypomethylated 0 0 0 0 2 3 2 10 10 12.8 1 5.9
Normal like 6 100 26 100 63 97 18 90 68 87.2 16 94.1
Hypermethylated 0 0 0 0 0 0 0
CDKN2A Hypomethylated 0 0 0 0 0 0 0 0
Normal like 6 100 26 100 60 92.3 18 90 61 67.8 14 70
Hypermethylated 0 0 5 7.7 2 10 29 32.2 6 30
ESR1 Hypomethylated 0 0 0 0 0 0 0 0 0
Normal like 6 100 26 100 63 97 19 95 63 98.4 19 100
Hypermethylated 0 0 2 3 1 5 1 1.6 0
FOXC1 Hypomethylated 0 0 0 0 0 0 0
Normal like 6 100 6 23 34 52.3 7 35 40 46.5 10 47.6
Hypermethylated 0 20 77 31 47.7 13 65 46 53.5 11 52.4
GSTP1 Hypomethylated 0 0 1 3.8 0 0 0 0
Normal like 6 100 10 38.5 27 41.5 5 25 29 33 5 25
Hypermethylated 0 15 57.7 38 58.5 15 75 59 67 15 75
IGF2 Hypomethylated 0 0 11 42.3 25 38.4 6 30 34 39.1 9 47.4
Normal like 6 100 14 53.8 32 49.2 9 45 32 36.8 5 26.3
Hypermethylated 0 0 1 3.9 8 12.4 5 25 21 24.1 5 26.3
MGMT Hypomethylated 0 0 0 13 20.3 13 65 16 24.2 8 44.4
Normal like 6 100 25 96.1 50 78.1 5 25 35 53.1 5 27.7
Hypermethylated 0 1 3.9 1 11.6 2 10 15 22.7 5 27.7
MLH1 Hypomethylated 0 0 4 15.4 12 18.5 6 32 4 4.5 3 17.6
Normal like 6 100 21 80.8 47 72.3 10 53 68 77.3 13 76.5
Hypermethylated 0 1 3.8 6 9.2 3 16 16 18.2 1 5.9
PPP2R2B Hypomethylated 0 0 0 0 0 0 0
Normal like 6 100 7 26.9 15 24.6 6 35 40 30.8 3 16.7
Hypermethylated 0 19 73.1 46 75.4 11 65 45 69.2 15 83.3
PTEN Hypomethylated 0 0 0 0 0 0 0
Normal like 6 100 21 80.8 56 86.2 13 65 23 27.7 9 45
Hypermethylated 0 5 19.2 9 13.8 7 35 60 72.3 11 55
RASSF1A Hypomethylated 0 0 2 7.7 2 3.1 1 0 0
Normal like 6 100 2 7.7 10 15.4 2 11 3 4.8 1 5.6
Hypermethylated 0 22 84.6 53 81.5 17 90 60 95.2 17 94.4
Samples were considered as hypermethylated if the% DNA methylation was higher than the sum of two times the standard deviation and mean of the normal
samples and hypomethylated if% DNA methylation was lower than two times the standard deviation - mean of the normal samples.
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the sum for the 12 genes was calculated giving one single
value (Z-score) for each sample. The false discovery rate
was not considered in this study due to small number ofgenes which were tested. All calculations were performed
using Statistical Package for Science version 18.
Univariate, Kaplan-Meier analyses and the log-rank
test for each parameter for single gene was performed to
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Further, multivariate, the Cox proportional hazard model
was used to identify independent prognostic markers for
all genes and from all clinical parameters: age, stage,
tumor size and grade, lymph node status, TP53 mutation
status, ER, PR status, T status. Methylation status of all
genes was treated as continuous and categorical. We
constructed possible model candidates using all combina-
tions of given variables. To select the best-fitted model
from all candidates, we evaluated the Akaike Information
Criterion (AIC) [17]. AIC gives an evaluation for model
selection, which is modified by a penalty increasing with
the number of variables of the model. Analyzing all
combinations of given variables we selected the model
that fitted best to the data indicated by a minimal value
for the AIC.
Results
Methylation analysis and correlation with
clinico-pathological parameters: stage and grade
A total of 48790 epigenotypes were generated through ana-
lyses of 205 CpGs in 12 genes (ABCB1 (20 CpGs), BRCA1
(19 CpGs), CDKN2A (28 CpGs), ESR1 (21 CpGs), FOXC1
(9 CpGs), GSTP1 (21 CpGs), IGF2 (17 CpGs), MGMT (9
CpGs), MLH1 (16 CpGs), PPP2R2B (14 CpGs), PTEN (19
CpGs) and RASSF1A (12 CpGs)). Six normal samples
were used to estimate the normal-like methylation levels
for all analyzed genes. Our analysis showed that five genes
ABCB1, FOXC1, GSTP1, PPP2R2B and RASSF1A were
the most frequently hypermethylated genes in all invasive
samples as well as in the DCIS samples. PTEN was
hypermethylated in invasive cancer of stage II, III and IVFigure 1 Average percentage of DNA methylation levels for all CpGs betand MGMT was hypomethylated in invasive tumors of
stage II, III and IV. CDKN2A had a normal-like methyla-
tion level in a high percentage of the DCIS samples and
early stage tumors. In late stage tumors CDKN2A showed
higher percentage of hypermethylated samples compared
to the early stage tumors and the DCIS. The methylation
levels of ESR1 and MLH1 were normal-like both in the
DCIS and the invasive tumors and BRCA1 had a normal-
like methylation level in almost all the DCIS and all invasive
tumors (Table 3.).
Significant differences in methylation levels between the
DCIS and invasive stage II tumors were observed for six
genes RASSF1A, CDKN2A, MGMT, ABCB1, GSTP1 and
FOXC1 (p = 0.008, p = 0.005, p = 0.003, p = 0.006, p = 0.010,
p = 0.010 respectively). RASSF1A, ABCB1 and GSTP1
showed significantly higher quantitative methylation levels
in late stage compared to the early stage breast carcinoma.
The most significant differences in methylation levels for
these three genes were between stage I and III (p = 0.001,
p = 0.022, p = 0.019 respectively) and between stage I and
IV (p = 3.3e-6, p = 0.030 and p = 0.014 respectively). PTEN
and CDKN2A methylation levels were low and increased
in late stage III and IV (p = 0.003, p = 0.004 between stage
I and III, p = 0.018 and p = 0.003 between stage I and IV),
while MGMT methylation levels were low and appear
to decrease with tumor stage (p = 4.5e-4 between stage
I and IV) (Figure 1). After correction for multiple testing
(Bonferroni correction), differences in methylation levels
for RASSF1A between stage I and III and stage I and IV
remained significant. Absolute differences in mean methy-
lation levels for RASSF1A were higher than 10%. For PTEN,
CDKN2A, MGMT methylation levels between stage I andween normal, DCIS and invasive tumor samples (stage I, II, III and IV).
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tion. Differences in methylation levels between the DCIS
and invasive stage II tumors for MGMT also reached
statistical significance after correction. Absolute differences
in mean methylation levels between different stages for
PTEN, CDKN2A, MGMT were less than 3% even though
they remained significant after Bonferroni correction.
We next combined all the methylation data into a single
variable, the methylation index, to investigate further,
how methylation levels change during progression of
breast cancer. At the same time we wanted to investigatea
b
Figure 2 Boxplots illustrating significant association between methyla
methylation levels in DCIS and stage I samples compared to stage II, III and
lower methylation index compared with grade 2 and grade 3 tumors.the presence of general pattern which might be more
robust than single genes. As shown in Figure 2, we ob-
served significantly lower methylation levels in DCIS
and stage I samples compared to stage II, III and IV
samples (p = 3e-7). Significant differences in methylation
levels were observed between the normal breast tissue and
stage II, III and IV tumors (p = 0.001, p = 0.006, p = 0.009
respectively). Normal breast tissue showed lower levels
of methylation compared with tumors mentioned above.
There was no significant difference observed between the
normal samples and the DCIS and stage I tumors. Alsotion status and tumor stage and grade. (a) Significantly lower
IV samples was observed. (b) Also grade 1 tumors had significantly
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than grade 1 tumors (p = 0.022). Methylation index analysis
showed that Luminal A and Luminal B tumors had signifi-
cantly higher Z-scores than Basal-like tumors (p = 0.007).
Correlation with TP53 mutations and hormone
receptor status
We compared the DNA methylation profiles with the
TP53 mutations status and found that tumors with TP53
mutations had significantly lower DNA methylation levels
then tumors with TP53 wild type in RASSF1A, PTEN,
PPP2R2B, FOXC1, ABCB1 and BRCA1 (p = 0.028, p =
0.031, p = 0.002, p = 0.017, p = 0.010, p = 0.001 respect-
ively). After Bonferroni correction DNA methylation
levels in PPP2R2B and BRCA1 were still significantly
lower in tumors with TP53 mutations. Significant associa-
tions with (ER) estrogen receptor status were observed
for RASSF1A, PPP2R2B, GSTP1 and FOXC1 methylation
levels (p = 0.004, p = 0.012, p = 0.012, p = 0.032, respect-
ively). HER2 receptor status was associated with RASSF1A,
PTEN, MGMT, CDKN2A and ESR1 (p = 0.023, p = 3.6e-7,
p = 1.1e-8, p = 5.8e-9, p = 0.017) and after Bonferroni
correction PTEN, MGMT and CDKN2A remained signifi-
cant. No significant association with (PR) progesterone
receptor status was observed (Table 4). Mann–Whitney
test revealed that ER and HER2 negative tumors had
lower methylation levels compared with ER and HER2
positive tumors for all studied genes. Interestingly HER2
negative tumors had higher methylation levels of ESR1
compared with HER2 positive tumors (p = 0.017). Z-score
analysis showed that TP53 mutated tumors had signifi-
cantly lower overall methylation levels compared to
tumors with wild type TP53. Also HER2 positive tumorsTable 4 Associations between methylation status and
TP53 mutation and hormone receptor status
GENE TP53 wt/mut p-value ER pos/neg
p-value
HER2 pos/neg
p-value
WT%
meth
Mut%
meth
p-value
BRCA1 87.34 79.99 0.001
PTEN 5.34 4.67 0.031 3.6e-6
PPP2R2B 11.33 9.47 0.002 0.012
FOXC1 17.12 13.56 0.017 0.032
ABCB1 14.52 10.28 0.010
RASSF1A 32.48 26.58 0.028 0.004 0.023
GSTP1 0.012
CDKN2A 5.8e-9
MGMT 1.1e-7
ESR1 0.017
Indicated are % methylation within the studied subgroups together with
p-values for differences in DNA methylation levels between genes in
connection with ER, HER2 and TP53 mutation status. Mann–Whitney test.had significantly higher z-scores of methylation compared
to the HER2 negative tumors (Figure 3). There was no
significant association with PR and ER status.
Survival analysis
To investigate which parameters contribute to differences
in survival we applied: 1) univariate analysis using Kaplan-
Meier modeling and the log-rank test for each gene and
each clinical parameter and 2) multivariate analysis using
Cox hazard proportional model to all variables. To select
the best-fitted model from all model candidates, we
evaluated the Akaike Information Criterion [17].
Univariate survival analysis identified methylation status
of PPP2R2B as significant predictor of overall survival. As
expected, grade, estrogen receptor status, TP53 status and
stage also appeared as significant predictors of survival.
The Kaplan-Meier plot (Figure 4) showed a significant
difference in survival between hypermethylated and
normal-like samples for PPP2R2B (p = 0.012) indicating
that patients with hypermethylated genes had better
survival. Breast cancer specific survival was significantly
improved in patients with hyper-methylated promoters
for PPP2R2B (p = 0.012).
Further, multivariate survival analysis was performed in
order to investigate if any of the methylation markers were
independent prognostic markers, using both, categorical
and continuous methylation data. We constructed possible
model candidates using all relevant parameters and
methylation data. Using calculated AIC, the best model
that fits to the survival data was assessed. For categorical
methylation data AIC identified a model explaining
survival, which included the methylation status of IGF2,
GSTP1, estrogen receptor status,TP53, N status and stage.
The estimated coefficients, the hazard ratio, the p-values,
and the 95% confidence intervals of the hazard ratio were
summarized in Table 5. For continuous methylation data
the best model explaining survival included TP53, T
status, N status, estrogen receptor status and methylation
status of IGF2 and GSTP1. The estimated coefficients,
the hazard ratio, the p-values, and the 95% confidence
intervals of the hazard ratio were summarized in Table 6.
For both, categorical and continuous methylation data
IGF2 and GSTP1 (p = 0.009 and p = 0.014) were significant
together with ER status (p = 0.008), TP53 status (p = 6.6e-5)
and N status (p = 0.047). For these models, we also de-
scribed statistical significance for the likelihood ratio,
Wald and log-rank tests in the Tables 5 and 6.
Discussion
The aim of this study was to quantitatively determine the
methylation levels in the promoter region of 12 genes in
breast cancer patients of all stages and to investigate stage
specific changes in tumors. In addition, we wanted to
evaluate the association between clinico-pathological
Figure 3 Boxplots illustrating significant association between methylation status and HER2 and TP53 status. (a) TP53 mutated tumors
had significantly lower overall methylation levels compared to tumors with wild type TP53. (b) HER2 positive tumors had significantly higher
methylation index compared to the HER2 negative tumors.
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methylation levels of these genes.
In the present study, five genes, ABCB1, FOXC1,
GSTP1, PPP2R2B and RASSF1A were hypermethylated
already in early stage breast cancer (stage I and II). For all
five genes hypermethylation was also detected in DCIS
suggesting that inactivation of these genes is a frequent
event in the process of mammary tumorigenesis. We found
that RASSF1A was hypermethylated in approximately 85%
of all invasive tumors and DCIS, and our results are in
agreement with such a high incidence of RASSF1A methy-
lation [18-20]. RASSF1A is a putative tumor-suppressor
gene. It belongs to an increasing list of tumor suppressor
genes that are frequently inactivated by promoter methy-
lation rather than by somatic mutations [21]. Since wedetected a constant hypermethylation of RASSF1A in all
of the different stages of the breast carcinomas we can
suggest that hypermethylation of RASSF1A is an early
event during breast cancer pathogenesis and also the main
mechanism of inactivation. In our study, GSTP1 was
found to be hypermethylated in different stages of breast
carcinomas, for early stages (I and II) our results are in
agreement with previous reports [22,23]. The frequency of
GSTP1 promoter hypermethylation in stage III and IV
(around 70%) was found to be higher than reported
previously [23,24]. It is known that GSTP1 plays a role
in detoxification of potential carcinogens and that loss
of the expression of GSTP1 will lead to DNA damage
of breast cells and they will be more easily exposed to
carcinogens [25]. Loss of GSTP1 expression and its
Figure 4 Kaplan-Meier plots of overall survival for patients with normal-like or hyper methylated PPP2R2B promoter. The p value was
calculated using a long-rank test.
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high proportion of breast tumors [23]. It appears that
promoter hypermethylation is associated with loss of
GSTP1 expression [26]. Important question is when
the promoter hypermethylation of the GSTP1 gene starts
to play a role in tumor progression? We found that already
in DCIS there is a high proportion of hypermethylated
GSTP1 (58%), which indicates that GSTP1 promoter hyper-
methylation is an early event in breast carcinogenesis. From
our analysis we observed that hypermethylation of ABCB1,
PPP2R2B and FOXC1 is also an early event in breast
carcinogenesis since our results indicate high level of
hypermethylation of these genes already in DCIS which
was reported before [4]. We found frequencies of
methylation for CDKN2A MGMT and MLH1 similar toTable 5 Multivariate survival analysis - categorical methylatio
Covariate Baseline Coefficient(bi)
TP53 TP53 wild type −2.332
ER ER positive 1.481
Stage II Stage I 2.260
Stage III Stage I −0.011
N1 N0 −6.362
N2 N0 1.673
IGF2 Normal like IGF2 1.597
GSTP1 Normal like GSTP1 −1.621
PPP2R2B Normal like PPP2R2B −0.972
CDKN2A Normal like CDKN2A −0.839
The variables that the minimum AIC selected. ( p-values: 3.4e-7 for likelihood ratio t
Positive hazard ratios indicate an increased risk of dying from breast cancer and arepreviously published reports [27,28]. According to our
results, we could suggest that hypermethylation of CDKN2A
is possible event leading to its inactivation in late stage
breast cancers. PTEN is a tumor suppressor gene. Its
product PTEN protein works as a negative regulator of
the Akt pathway, leading to suppression of apoptosis and
increasing cell survival [29]. We suggest here that epigen-
etic silencing of PTEN might be an early event in initiation
of cancer and also the mechanism of its inactivation. Next,
combining all the methylation data into a single variable,
the methylation index, we investigate how methylation
levels change during progression of breast cancer. Our
analysis showed that the methylation pattern of all
genes included in this study is changing during breast
cancer progression. DCIS and stage I tumors had similarn data
HR(exp(bi) p-value 95,0%CI for Exp(B)
0.097 6.6e-5 (0.030-0.305)
4.401 0.008 (1.460-13.269)
9.584 0.013 (1.593-57.667)
0.988 0.992 (0.088-11.019)
0.529 0.338 (0.143-1.947)
5.332 0.047 (1.019-27.885)
4.940 0.009 (1.472-16.581)
0.197 0.014 (0.053-0.729)
0.378 0.085 (0.125-1.143)
0.432 0.133 (0.144-1.294)
est, 3.4e-4 for Wald test, 3.2e-6 for log-rank test).
calculated for the different covariates.
Table 6 Multivariate survival analysis - continuous methylation data
Covariate Baseline Coefficient (bi) HR(exp(bi) p-value 95,0% CI for Exp(B)
GSTP1 Normal like GSTP1 −0.066 0.935 4e-4 (0.902-0.970)
IGF2 Normal like IGF2 0.079 1.082 0.002 (1.031-1.136)
MLH1 Normal like MLH1 −0.552 0.575 0.135 (0.278-1.187)
ER ER positive 1.659 5.256 0.002 (1.804-15.317)
TP53 TP53 wild type −2.169 0.114 0.002 (0.028-0.450)
N 1 N0 1.684 5.391 0.022 (1.265-22.975)
N 2 N0 1.706 5.511 0.032 (1.151-26.371)
T 2 T1 1.937 6.942 0.035 (1.143-42.157)
T3 T1 0.050 1.051 0.960 (0.143-7.716)
T4 T1 1.125 3.081 0.258 (0.437-21.692)
The variables that the minimum AIC selected. ( p-values: 1.2e-7 for likelihood ratio test, 5.8e-4 for Wald test, 6.7e-6 for log-rank test).
Positive hazard ratios indicate an increased risk of dying from breast cancer and are calculated for the different covariates.
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http://www.biomedcentral.com/1471-2407/13/456methylation levels with no significant difference. Stage II
tumors showed the most significant difference in methyla-
tion levels when compared with DCIS and stage I and
then in stage III and IV methylation levels were lower but
still significantly higher than in DCIS and stage I. It
remains unclear how this process of dramatic change in
stage II is achieved and driven further during breast
cancer progression. To our knowledge only one group
investigate stage dependent DNA methylation in breast
cancer using DCIS and all four stages of invasive tumors
[30]. They identified 33 cancer specific genes that were
either highly methylated in early stage breast cancer or
showed stage dependent methylation pattern, lower
methylation frequency in early stage breast cancers and a
higher methylation frequency in late stage breast cancers.
None of our selected genes were methylated in this study.
Additional studies of the relationship between DNA
methylation in tumors and tumor stages are necessary.
In the present study we showed the associations be-
tween DNA methylation levels of candidate genes and
the TP53 mutation status, estrogen receptor status,
and HER2 status. The TP53 tumor suppressor gene has
a central role in cell cycle regulation, DNA repair and
apoptosis, and a large number of reports have discussed
the important role of TP53 alterations in breast cancer.
Also, a number of studies have shown that breast tumors
with TP53 mutations are strongly associated with poor
prognosis and lacking methylation in a number of regula-
tory genes [31,32]. Additionally, studies on different
expression subtypes in breast cancer showed that different
subtypes have a different underlying biology reflected in
methylation and is strongly influenced by TP53 mutation
status. It was shown that basal-like tumors are TP53 mu-
tated and unmethylated [6,33]. In present study we have
identified 26,6% of breast tumors with TP53 mutations
and significantly lower levels of DNA methylation in
RASSF1A, PTEN, PPP2R2B, FOXC1, ABCB1 and BRCA1compared to tumors with wild type TP53. Since in our
study we had low number of basal-like tumors (37 out of
238) we cannot confirm association between TP53 mu-
tated and unmethylated tumors and basal-like but most of
the basal-like samples were TP53 mutated and had lowest
methylation levels compared to other subtypes (data not
shown). The status of ER and HER2 have been recognized
as important prognostic factors in patients with breast
cancer, in addition to a predictive marker for the response
to treatment with endocrine and trastuzumab therapy.
Identification of genes with subtype-specific methylation
revealed that RASSF1A and GSTP1 were highly methylated
in Lum B tumors [33]. These two genes were reported pre-
viously to be significantly more methylated in ER- positive
than ER-negative tumors [34]. In the present study we
showed the same trend in ER-positive tumors compared to
ER-negative for four genes and RASSF1A and GSTP1 were
among them. The same group reported that HER2 positive
tumors had higher methylation level for these two genes
compared to HER2-negative tumors, which is again in
accordance with our study. Furthermore, in a study on
methylation in breast cancer and breast cancer molecular
subtypes it was shown that RASSF1A is hypermethylated
in HER2 positive breast tumors (ERBB2 and luminal B)
[35]. In our study RASSF1A was hypermethylated in
ERBB2 and luminal B tumors (data not shown). Taken all
together, these results, suggest that methylation plays a
significant role in the different breast tumor phenotypes.
We report here for the first time the PPP2R2B
methylation status as significant predictor for breast
cancer survival as well as for overall survival. PPP2R2B
is a candidate tumor suppressor gene and it was shown
that changes in DNA methylation of this gene contribute
to its expression [36]. Further, multivariate analysis showed
that IGF2 and GSTP1 were independent prognostic
markers. Recently, it has been shown that the absence
of GSTP1 protein expression correlate with promoter
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http://www.biomedcentral.com/1471-2407/13/456hypermethylation and with improved survival in invasive
breast cancer samples [37]. Hypermethylation of GSTP1
is a well established biomarker for hormone dependent
cancers. Our previous analyses suggest that methylation
of GSTP1 in locally advanced breast cancer patients treated
with doxorubicin was associated to survival [3]. However,
GSTP1 had no effect on treatment response.
Conclusions
Here we report aberrant methylation levels of ABCB1,
FOXC1, GSTP1, PPP2R2B and RASSF1A in DCIS and
stage I-IV providing evidence that suggests that changes
in methylation level is an early event and may also be
important in progression to later stages of breast cancer.
We also report that methylation levels of important breast
cancer genes are associated to hormone receptor status
and TP53 mutation status suggesting mechanisms of
deactivation of tumor suppressor genes in breast cancer.
Further studies are necessary to identify which methylation
gene profiles are of predictive and which of prognostic
value.
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